Dimitris Voliotis has been appointed chief development officer of German biotech CureVac. Voliotis, who was most recently senior vice president and head of global clinical development for Eisai, will work from CureVac’s Boston office. CureVac is developing messenger RNA drugs intended to deliver the genetic instructions that enable a patient’s cells to produce therapeutic proteins.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
